Solana (NASDAQ:HSDT) Given New $2.50 Price Target at B. Riley Financial

Posted by on Aug 17th, 2026

Solana (NASDAQ:HSDT – Get Free Report) had its target price cut by research analysts at B. Riley Financial from $3.00 to $2.50 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s target price indicates a potential upside of 48.37% from the stock’s current price.

A number of other research firms also recently issued reports on HSDT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Solana in a report on Friday, July 17th. Zacks Research upgraded Solana to a “hold” rating in a research note on Monday, April 27th. Finally, Wall Street Zen downgraded Solana from a “hold” rating to a “sell” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.25.

View Our Latest Analysis on HSDT

Solana Price Performance

HSDT stock traded down $0.01 during trading hours on Monday, reaching $1.69. 71,102 shares of the stock were exchanged, compared to its average volume of 344,833. The firm’s 50-day moving average is $1.67 and its 200-day moving average is $1.94. The company has a market cap of $98.39 million, a price-to-earnings ratio of -0.06 and a beta of 1.01. Solana has a 12 month low of $1.19 and a 12 month high of $25.50.

Solana (NASDAQ:HSDT – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.36). The firm had revenue of $2.53 million during the quarter, compared to analyst estimates of $3.50 million. Solana had a negative net margin of 1,302.78% and a negative return on equity of 46.41%. As a group, equities research analysts forecast that Solana will post -0.09 earnings per share for the current year.

Institutional Trading of Solana

Several institutional investors and hedge funds have recently added to or reduced their stakes in HSDT. Franchise GP Ltd bought a new position in shares of Solana in the 4th quarter valued at about $653,000. Geode Capital Management LLC acquired a new stake in Solana in the 4th quarter valued at about $1,006,000. LPL Financial LLC grew its holdings in Solana by 120.1% during the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock worth $1,105,000 after purchasing an additional 208,558 shares during the period. Aristides Capital LLC acquired a new position in Solana during the fourth quarter worth approximately $137,000. Finally, State Street Corp acquired a new stake in shares of Solana in the fourth quarter valued at approximately $464,000. 18.63% of the stock is owned by institutional investors.

Solana Company Profile

(Get Free Report)

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.

Featured Articles

Receive News & Ratings for Solana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solana and related companies with MarketBeat.com's FREE daily email newsletter.